Eli Lilly and Company Reaffirms its Earnings Guidance for the Year 2012 and Provides Earnings Guidance for the Year 2013 an 2014
For 2013, the company expects earnings per share to be in the range of $4.03 to $4.18 on a reported basis, or $3.75 to $3.90 on a non-GAAP basis when excluding an estimated $0.28 per share of exenatide-related income contingent upon the transfer of exenatide commercial rights outside the U.S. to Amylin. The company anticipates 2013 revenue of between $22.6 billion and $23.4 billion. On a reported basis, the 2013 tax rate is expected to be approximately 22.5%, assuming a full-year 2013 benefit of the R&D tax credit. On a non-GAAP basis, the 2013 tax rate is expected to be approximately 21%. Operating cash flows are expected to be more than sufficient to allow for capital expenditures of approximately $900 million.
From now through 2014, on an annual basis the company still expects revenue to be at least $20 billion, net income to be at least $3 billion, and operating cash flow to be at least $4 billion.